NCT06863402 is a Phase 2 clinical trial of Biospecimen Collection in Richter Syndrome, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT06863402?

NCT06863402 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT06863402?

Interventions in NCT06863402: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Multigated Acquisition Scan, Nemtabrutinib, Pembrolizumab, Positron Emission Tomography, Questionnaire Administration.

What condition does NCT06863402 study?

NCT06863402 studies Richter Syndrome, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia.

Is NCT06863402 still recruiting?

NCT06863402 is currently recruiting now. Last updated 24 March 2026.

Last reviewed 2026-03-24 · How we verify

NCT06863402

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Recruiting now Phase 2 Last updated 24 March 2026

What this trial tests

Phase 2 trial testing Biospecimen Collection in Richter Syndrome in 32 participants. Currently enrolling.

Timeline

15 April 2026

Primary endpoint
1 April 2029

1 April 2030

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	15 April 2026
Primary completion	1 April 2029
Estimated completion	1 April 2030
Sites	1 location across United States

Drugs / interventions tested

Biospecimen Collection — full drug profile →
Bone Marrow Biopsy
Computed Tomography
Echocardiography
Multigated Acquisition Scan
Nemtabrutinib — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →
Positron Emission Tomography
Questionnaire Administration

Conditions studied

Richter Syndrome — all drugs for Richter Syndrome →
Diffuse Large B-Cell Lymphoma — all drugs for Diffuse Large B-Cell Lymphoma →
Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →

Sponsor

Roswell Park Cancer Institute

Who can join

18 and older, any sex, with Richter Syndrome or Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as Richter transformation at abnormal levels. This may help keep cancer cells from growing and spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving nemtabrutinib in combination with pembrolizumab may kill more cancer cells in patients with RT-DLBCL.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Pathogenesis and Targeted Treatment of Richter Transformation
Maher N, Karami A, Matti B, Alwan A, et al · · 2026
Efficacy and safety of BTK inhibitors in Richter's transformation: a systematic review of clinical evidence.
Dirican CD, Ajayi F, Al Mardini A, Crocete Aloysia Fernandes B, et al · · 2025 · PMID 41640437 · DOI 10.3389/fonc.2025.1681589
Richter's transformation: status quo and quo vadis.
Khalifa IM. · · 2025 · PMID 41238946 · DOI 10.1007/s00277-025-06622-5

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting

Other recruiting trials for Richter Syndrome

Currently open trials in the same condition.

NCT06735664 — Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation · Phase 1 · recruiting
NCT06676033 — Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome · Phase 1 · active not recruiting
NCT06926205 — CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL · Phase 2 · recruiting
NCT06186648 — Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter S · Phase 2 · recruiting
NCT05672173 — Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation · Phase 2 · recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06863402 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 24 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06863402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing